The development of therapeutic resistance to targeted anticancer therapies remains a
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context …

Survivin, as a member of the inhibitor of apoptosis proteins (IAPs) family, acts as a
suppressor of apoptosis and plays a central role in cell division. Survivin has been …

The acquisition of cancer cell resistance to conventional chemotherapeutics is considered
the major driver of treatment failure and disease recurrence in most solid and hematological …

Cancer is a heterogeneous disease with unique genomic and phenotypic features that differ
between individual patients and even among individual tumor regions. In recent years, large …

Rapid progress in genome sequencing technology has put us firmly into a postgenomic era.
A key challenge in biomedical research is harnessing genome sequence to fulfill the …

Introduction: Anticancer tyrosine kinase inhibitors (TKIs) are small molecule hydrophobic
compounds designed to arrest aberrant signaling pathways in malignant cells. Multidrug …

Cancer treatment is undergoing a significant revolution from “one‐size‐fits‐all” cytotoxic
therapies to tailored approaches that precisely target molecular alterations. Precision …

Small molecule therapy is a critical component of targeted anticancer treatment, with
tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic …

The discovery of the chimeric tyrosine kinase breakpoint cluster region kinase-Abelson
kinase (BCR-ABL)-targeted drug imatinib conceptually changed the treatment of chronic …

Some cases of chronic myelogenous leukemia are resistant to tyrosine kinase inhibitors (TKI
s) independently of mutation in BCR–ABL, but the detailed mechanism underlying this …